Loading...
Publication
Impact of 13-valent pneumococcal conjugate vaccination introduction in children on pneumonia hospitalizations among adults aged 65 or more in Portugal
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.02 MB | Adobe PDF | |||
| 62.48 KB | Adobe PDF |
Advisor(s)
Abstract(s)
The incidence of pneumonia and pneumonia related hospitalizations still increasing in different European and American Countries. However, in western countries this increase is driven by secondary diagnoses, recurrent pneumonia episodes in elderly and among those with comorbidities. Given the high frequency of Streptococcus pneumoniae among all pneumonia, it is reasonable to expect that a wide use of pneumococcal vaccines would reduce the burden of pneumonia in the elderly due to a direct and indirect effect. In Portugal, pneumococcal vaccines are available since 1996: pneumococcal polysaccharide vaccine (PPSV23) in 1996; heptavalent conjugated pneumococcal vaccines (PCV7) in 2001; PCV10 in April 2009 and PCV13 in January 2010. PPSV23 and PCV13 are widely recommended for risk groups and elderly. PCV7 serotypes reduced from 31% in 1999–2003 to 11% in 2009–2011 in non-invasive pneumococcal pneumonia (PP), but no decreasing trend was observed for PCV13 and PPSV23 serotypes until 2011. Trends in pneumococcal pneumonia after PCV13 introduction are not known in Portugal. Thus, this study aims to assess population level impact of infant PCV13 introduction on burden of pneumonia among adults aged 65 or more in Portugal through comparison of trends in PP hospitalization rates before and after PCV13 introduction.
Description
Resumo publicado em: Revue d'Épidémiologie et de Santé Publique. 2018 Jul;66(Suppl. 5):S363-64. Disponível em: https://www.sciencedirect.com/science/article/pii/S0398762018310460
Keywords
13-valent Conjugated Pneumococcal Vaccine Interrupted Time Series Analysis Hospitalization Older Adults Pneumococcal Pneumonia Determinantes da Saúde e da Doença Estados de Saúde e de Doença